ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases and oncology. Founded in 2002 and headquartered in Singapore, the company has grown to maintain a global footprint with additional offices in the United States, Australia, and Europe. ASLAN leverages its proprietary platform technologies and deep expertise in medicinal chemistry to advance small-molecule and antibody candidates through clinical development.
The company’s lead asset, uzamilimab (ASLAN004), is a humanized monoclonal antibody targeting ICOS ligand for the treatment of immune-mediated conditions such as dermatomyositis and other rare autoimmune diseases. In parallel, ASLAN is advancing ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), through clinical trials in inflammatory bowel disease and other T-cell–mediated disorders. Both programs reflect ASLAN’s strategic focus on addressing high-unmet needs with first- or best-in-class treatments.
ASLAN’s oncology pipeline includes ASLAN101, a small-molecule inhibitor designed to modulate the tumor microenvironment by targeting key kinases involved in immune suppression. This program underscores the company’s commitment to harnessing the immune system to improve cancer outcomes. Across its portfolio, ASLAN collaborates with academic institutions and industry partners to accelerate research and optimize development pathways, ensuring robust scientific rigor and regulatory alignment.
Leadership at ASLAN Pharmaceuticals is headed by Chief Executive Officer Dr. William K.L. Tan, who brings extensive experience in drug discovery and global clinical development. The executive team includes veterans in regulatory affairs, medical affairs, and commercial strategy, positioning the company to efficiently transition candidates from bench to bedside. With a diversified pipeline and a commitment to innovation, ASLAN Pharmaceuticals aims to deliver transformative therapies to patients worldwide.
AI Generated. May Contain Errors.